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Alzheimer’s disease (AD), characterized by memory and cognitive deficits, is a progressive, 
irreversible neurodegenerative disease. A rising theory addressing AD development and 
progression is the Ca2+ hypothesis, suggesting that Ca2+ dyshomeostasis can result in 
neuropathological lesions observed in AD patients. Previous studies have shown that 
ryanodine type II receptors (RyR2), predominantly expressed in the heart, have a high 
expression in hippocampal neurons, and that Ca2+ leak through RyR2 leads to AD-like 
symptoms. FKBP12.6, a regulatory protein that forms a complex with RyR2, modulates Ca2+ 
release by manipulating RyR2 ultrastructural organization. Current treatment for AD is 
limited, with treatment having minimal effects in alleviating symptoms. S107, a RyR2-
specific Rycal, has shown to prevent FKBP12.6 depletion, therefore reducing Ca2+ leak by 
stabilizing the RyR2-FKBP12.6 interaction. We propose to determine how S107 alters Ca2+ 
leak, and ultrastructural RyR2 and FKBP12.6 arrangement in HEK293 cells by performing 
real-time Ca2+ imaging, confocal microscopy, and super-resolution microscopy. If S107 acts 
in a similar manner as it does in the heart, this may provide a novel treatment for preventing 
Ca2+ leak in AD. HEK293-RyR2WT-expressing cells were either mock transfected or 
transfected with FKBP12.6 cDNA. Cells were incubated in either 10 µM DMSO or S107. 
Our functional Ca2+ assay using a ratiometric dye, Fura-2AM, showed that when exposed to 
increasing Ca2+ concentrations (0.1 mM, 0.2 mM, 0.3 mM, 0.5 mM, 1 mM), FKBP12.6 
significantly reduced Ca2+ leak, and that S107 further reduced Ca2+ leak significantly only in 
the presence of FKBP12.6 (p<0.05). The amount of Ca2+ released by RyR2 was also 
significantly reduced (p<0.05) when FKBP12.6 and S107 were present (85.54% ±1.26% vs. 
72.66% ± 3.88% respectively; p<0.001). Our structural assay was able to determine that (1) 
FKBP12.6 was present in RyR2 HEK293 cells transfected with FKBP12.6 and (2) that there 
 iii 
is no significant difference (p>0.05) between RyR2-only cells and RyR2 cells with a 
combination of FKBP12.6 and S107 in RyR2 count, spread, and density. Future research can 
explore these aspects in cultured AD neurons, as well as looking at other forms of imaging, 
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1.1 Alzheimer’s disease (AD) 
1.1.1 AD epidemiology and symptoms 
Alzheimer’s disease (AD), characterized by memory and cognitive deficits, is a progressive 
irreversible neurodegenerative disease (Van Acker et al., 2019). AD patients are categorized 
into one of three clinical stages: mild (early), moderate and severe stage (Zvěřová, 2019). This 
depends on the severity of the broad range of cognitive symptoms, such as a decline in episodic 
memory and visuospatial skills, and neuropsychiatric symptoms, such as apathy and psychosis 
(Apostolova, 2016). With 46 million people suffering from AD worldwide, it has been 
recognized as one of the most common forms of dementia, making up 50-75% of dementia 
patients in New Zealand (Eratne et al., 2018; Uddin et al., 2020). It is predicted that by 2031, 
the prevalence of AD will increase approximately 2.5 fold in the population (Tobias et al., 
2008). Despite therapeutic treatments available to AD patients to relieve them of their 
symptoms, these treatments alone are not enough to relieve individuals and society of the 
socioeconomic burden as the number of AD patients continues to increase. According to Ma’u 
et al. (2021), the total economic estimated cost of dementia for New Zealand in 2020 was $2.46 
billion.  
 
Patients develop two major hallmarks of AD: amyloid-beta (Aβ) plaques and neurofibrillary 
tangles (Kidd, 1963; Hellström-Lindahl et al., 2008). Whilst these lesions first localize and 
accumulate in the hippocampal region and amygdala of the brain, it progressively spreads to 
the cortex and other areas of the brain over time (Braak & Braak, 1997).  
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AD is divided into two types: familial and sporadic, with familial accounting for 1-5% of all 
AD diagnosed cases (Reitz & Mayeux, 2014). Causative mutations of familial AD have been 
identified in three proteins: the amyloid precursor protein (APP), and presenilin proteins 1 and 
2 (PS1 and 2) (Brunello et al., 2009). Until now, the mechanism of the development of sporadic 
AD is still unknown, however there are multiple hypotheses regarding the development and 
progression of AD in both sporadic and familial cases. 
 
1.1.2 The amyloid cascade hypothesis 
The amyloid cascade hypothesis is the leading proposed mechanism of the neuropathological 
progression of both familial and sporadic AD, and was first introduced by John Hardy and 
David Allsop in 1991. It states that increased amyloid-beta production or decreased amyloid-
beta clearance results in the development of both familial and sporadic AD (Hardy & Allsop, 
1991). Whilst this is the most popular AD hypothesis to date, there is still a lot of controversy 
surrounding the hypothesis. Consequently, recent AD studies have begun exploring an 
alternative hypothesis: the calcium hypothesis. 
 
1.1.3 The calcium hypothesis 
The calcium hypothesis, first introduced by Mattson (1992), suggests that calcium (Ca2+) 
dyshomeostasis precedes amyloid-beta plaque and neurofibrillary tangle formation, indicating 
it could be the root cause of these AD neuropathological lesions. Studies have shown that there 
is an association between Ca2+ dyshomeostasis and the development of AD-like symptoms 
(Giacomello et al., 2005; Brunello et al., 2009). Although Giacomello et al. (2005) saw 
decreases in Ca2+ intracellular concentrations with PS2 mutations whilst Brunello et al. (2009) 
saw increased Ca2+ leak upon the expression of mutant PS2 and also a reduction in the reuptake 
of Ca2+ into intracellular stores, this could be due to differences in PS2 mutations. It has been 
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proposed that the mutations in APP, PS1 or PS2 that are observed in AD patients lead to 
amyloid-beta generation. The generation of amyloid-beta can affect one of two pathways, both 
causing Ca2+ dyshomeostasis and ultimately resulting in the development of familial or 




1.1 Synaptic transmission 
Ca2+ acts as an important intracellular signalling molecule, particularly in synaptic transmission 
and plasticity in the brain (Cho et al., 2001; Mateos-Aparicio & Rodríguez-Moreno, 2020). 
Alterations in intracellular Ca2+ levels have shown to result in the development of 
neurodegenerative diseases, such as AD, Parkinson’s disease and Huntington’s 
disease (Giacomello et al., 2005; Suzuki et al., 2012; Hurley et al., 2013). 
 
1.1.1 Healthy neuronal synaptic transmission  
During healthy synaptic transmission, an action potential is propagated along a neuron to 
trigger the influx of Ca2+. This occurs through voltage-gated Ca2+ channels (VGCC), N-methyl-
D-aspartic acid receptors (NMDARs) and alpha-amino-3-hydroxy-methyl-4-isoxazole-
Figure 1.1 Pathway of the development and outcome of APP, PS1 and PS2 mutations. Adapted from 
(Berridge, 2010; Braunewell, 2012). Mutations in APP, PS1 or PS2 lead to amyloid-beta generation. This 
either results in amyloid-beta metabolism (red) or  RyR2 dysfunction (purple), both eventually resulting in 
Ca2+ dyshomeostasis and familial/sporadic AD development. Image made via BioRender. 
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propionate receptors (AMPARs) embedded in the pre-synaptic terminal of a neuron. 
Consequently, this increases cytosolic Ca2+ concentration, and this influx of Ca2+ triggers the 
opening of Ca2+-sensitive release channels embedded in the endoplasmic reticulum (ER) 
membrane: inositol 1,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RyR). The 
efflux of Ca2+ from the ER through these channels amplifies the Ca2+ signal, allowing for the 
release of neurotransmitters on the presynaptic terminal into the synaptic cleft to bind to their 
respective receptors on the postsynaptic terminal. The binding of the neurotransmitters to their 
receptors at the postsynaptic terminal causes further Ca2+-induced Ca2+ release (CICR) in the 
post-synaptic cell, releasing more Ca2+ via IP3R and RyR from the ER (Del Prete et al., 2014; 
Mateos-Aparicio & Rodríguez-Moreno, 2020). Removal of Ca2+ occurs through ER Ca2+ 
ATPase (SERCA), the mitochondrial uniporter, through the plasma membrane Ca2+ ATPase 




1.1.2 Altered synaptic transmission in AD  
Synaptic transmission in AD patients is altered due to excessive Ca2+ leak through the ER Ca2+ 
release channels, neurotransmitter deregulation, which leads to impaired synaptic plasticity and 
cognitive dysfunction (Hyman et al., 1987; Nazarali & Reynolds, 1992; Yuan et al., 2016; 
Snowden et al., 2019). It has been shown that neurotransmitter dysregulation at the synapse is 
correlated with cognitive dysfunction, with AD patients demonstrating a larger deficiency and 
depletion of neurotransmitters such as glutamate and acetylcholine which resulted in memory 
loss and impaired synaptic plasticity (Hyman et al., 1987; Nazarali & Reynolds, 1992; 
Snowden et al., 2019). 
Figure 1.2 Synaptic transmission in neurons. As an action potential is propagated along the presynaptic 
neuron (purple), the release of Ca2+ triggers CICR, causing the release of Ca2+ from the ER through RyR2 and 
IP3R. CICR triggers the release of neurotransmitters, which bind to their receptors on the postsynaptic terminal 




1.1.3 Synaptic plasticity  
Synaptic plasticity is the functional and/or structural changes made by neurons in order to 
strengthen or weaken synaptic transmission at a pre-existing synapse during learning and 
memory processes (Citri & Malenka, 2008). This can be divided into short-term and long-term 
plasticity. Short-term plasticity is characterized as a temporary enhancement of synaptic 
transmission before it reverts back to its initial state. On the other hand, repeated stimulation 
of these neurons, as opposed to temporary stimulation, results in long-term plasticity, causing 
a lasting change in the synaptic connection (Ohno et al., 2011). During long-term plasticity, 
we can encounter long-term potentiation (LTP) or long-term depression (LTD) (Malenka & 
Bear, 2004; Citri & Malenka, 2008). LTP refers to enhanced synaptic transmission which is 
long-lasting after high-frequency stimulation. On the contrary, LTD is a long-lasting decrease 
in synaptic transmission after low-frequency stimulation (Bliss & Gardner-Medwin, 1973; 
Bliss & Lomo, 1973; Del Prete et al., 2014). Previous studies have drawn a link between LTP 
and LTD to learning and memory, suggesting that intracellular Ca2+ stores, and their associated 
Ca2+ release channels (RyR2 and IP3R) play an important role in hippocampal LTP induction 
(Obenaus et al., 1989; Malenka, 1994; Wang et al., 1996; Pastalkova et al., 2006; Whitlock et 
al., 2006; Mellentin et al., 2007).  
 
 
1.2 Ryanodine receptors 
Ryanodine receptors (RyRs) are 565 kDa-sized homotetrameric Ca2+ release channels (2.2 
MDa for tetramer), making them the largest ion channels identified (Otsu et al., 1990; Zalk & 
Marks, 2017). Three isoforms of this receptor exist and are expressed in different tissues in the 
body: types I, II and III (Meissner, 2017). Embedded in the sarcoplasmic reticulum (SR) or 
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endoplasmic reticulum (ER) membrane, clusters of RyRs release Ca2+ from these internal Ca2+ 
stores (Cheng et al., 1993; Baddeley et al., 2009).  
 
1.2.1 Ryanodine type II receptors (RyR2) 
Despite all three isoforms present in the brain, RyR2 is predominantly found in the 
hippocampus at a high abundance in comparison to the other RyR isoforms (Giannini et al., 
1995; Galeotti et al., 2008). In neurons, RyR2 is located in the ER of axons and dendrites as 
well as the soma (Kass & Tsien, 1982; Sharp et al., 1993). Although the knowledge of RyR 
presence in the brain has existed for decades, there is still a lot of uncertainty surrounding its 
function and role in neurodegenerative diseases and a lot of what is known about RyR2 function 
in the brain has come from previous research completed in the heart. Studies based in both 
cardiac and brain tissue indicate that Ca2+ homeostasis is extremely important for both normal 
function and in disease, and that RyR2 plays a very important role in maintaining this 
homeostasis. 
 
1.2.2 RyR2 clustering in the heart 
Arranged in clusters, RyR2 has been shown to be organized depending on the isoform and the 
tissue that they are expressed in. Clusters are more organized units in some tissues such as 
skeletal muscle, forming a checkerboard or crystalline arrangement, whilst in other tissues such 
as the heart, clusters are less organized, forming “side-to-side” interactions (Asghari et al., 
2014; Jones et al., 2018; Asghari et al., 2020). Much of what is known of RyR2 clustering 
stems from studies in the heart. These studies are summarized below. Asghari et al. (2020), 
Xie et al. (2019), and Galice et al. (2018) highlighted the ultrastructural arrangement of RyR2 
in cardiomyocytes varied, and its ultrastructural variations in arrangement could be due to the 
modulation of Ca2+ release. Asghari et al. (2020) noted that in cardiomyocytes, the more 
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organized RyR2 clusters were (a checkerboard formation), the less abnormal Ca2+ release (Ca2+ 
leak) occurred. Ca2+ leak,  termed as store-overload-induced calcium release (SOICR), occurs 
when the SR or ER becomes overloaded with Ca2+. In turn, this leak can trigger CICR or 
uncontrolled Ca2+ release in the form of waves. These pathological release events occur either 
when Ca2+ concentrations are above threshold within the SR, or when RyR2 becomes more 
sensitive to activation by Ca2+ (Díaz et al., 1997; Boyden & Smith, 2018). Various studies have 
shown that changes in the cluster sizes of RyR2 can potentiate Ca2+ waves and that an excessive 
amount of Ca2+ leak can alter contractility in the heart. Consequently, this can trigger delayed-
after depolarizations (DADs), increasing the risk of occurrence of arrhythmias, which have 
shown to be a result of RyR2 dysfunction (Marban et al., 1986; Xie et al., 2019; Asghari et al., 
2020). Studies looking at RyR2 mutations, such as those causing catecholaminergic 
polymorphic ventricular tachycardia (CPVT), have shown RyR2 becomes more sensitive to 
SOICR. This has been shown to alter membrane potential, generating DADs and the potential 
of triggering arrhythmias (Jiang et al., 2004; Jiang et al., 2005). 
 
1.2.3 RyR2-mediated Ca2+ leak in relation to AD  
The following section summarizes the knowledge of Ca2+ leak in the brain. Although the 
mechanism of Ca2+ leak through RyR2 is common in the heart and brain, the term SOICR has, 
until recently, largely only been used in cardiac research. Therefore, when introducing neuronal 
Ca2+ homeostasis, the term ‘Ca2+ leak’ is used that is consistent with literature. However, this 
term can be used interchangeably with SOICR as has been done later in the thesis. In the brain, 
many studies have demonstrated that RyR2 plays an important role in modulating Ca2+ release 
and inappropriate release has a detrimental effect on cognition and memory. The outcomes of 
RyR2 downregulation have been demonstrated in multiple studies: loss of excitatory synapses, 
reduced dendrite density, reduced LTP, alterations in memory acquisition and circuitry. 
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Considering the observations made in studies, many deduced that these changes were similar 
to neuropathological lesions observed in neurodegenerative diseases such as AD (Liu et al., 
2012; More et al., 2018; Bertan et al., 2020).  
 
Brunello et al. (2009) highlighted that PS2 played a part in modulating Ca2+ release from the 
ER, increasing Ca2+  leak through RyR2. In the case of familial AD, this could suggest that the 
mutations observed in PS2 proteins in familial AD patients could have an effect on Ca2+  
homeostasis. Consequently, the excessive Ca2+ leak could lead to the development of AD 
neuropathological lesions, such as neurofibrillary tangles, which aligns with the Ca2+  
hypothesis. An emergent study has revealed specific binding sites on PS1 and 2 for Ca2+ that 




Figure 1.3 Summary of findings and conclusions made by Brunello et al. (2009). The presenilin-2 (PS2) 
protein (green)  inhibits SERCA, therefore reducing Ca2+ reuptake back into the ER (blue). The PS2 protein 
increases Ca2+ leak through the Ca2+ release channels in the ER, RyR2 and IP3R, thus increasing Ca2+ ER release 
(purple). Image made via BioRender. 
 
 10 
1.2.4 Modulating RyR2 activity 
As the Ca2+ hypothesis proposes that amyloid-beta generation leads to RyR2 dysfunction, 
researchers have explored certain RyR2 modulators that may either be upregulated or 
downregulated in AD patients, therefore affecting RyR2 activity.  
 
There are many proteins that have been shown to modulate RyR2 Ca2+ release in the heart, 
such as  FK506 binding protein 12 (FKBP12), protein kinase A (PKA), calmodulin-dependent 
kinase II (CaMKII), and FK506 binding protein 12.6 (FKBP12.6) (Györke & Terentyev, 2008; 
Walpoth & Erman, 2015; Uchinoumi et al., 2016). A study by McKee et al. (1990) showed 
that neurons exhibiting AD-like lesions had increased CaMKII levels, suggesting that CaMKII 
may play a role in Ca2+ dyshomeostasis. Studies have shown that phosphorylation of RyR2 by 
CaMKII results in increased Ca2+ leak out of RyR2, and that this could be due to its ability to 
dissociate FKBP from RyR2 (Wang et al., 2005; Ather et al., 2013; Okuda et al., 2018). 
Therefore, recent studies have begun to explore FKBP as a potential therapeutic target. 
 
1.3 RyR2 modulation by FKBP 
FKBP12 and FKBP12.6, also known as calstabin1 and 2 respectively, are two isoforms 
of  FK506 binding proteins (FKBP), which act as intracellular modulators (Lam et al., 1995). 
These ~12 kDa binding proteins regulate RyR activity by stabilizing the receptor in its closed 
state (Brillantes et al., 1994; Mayrleitner et al., 1994; Lam et al., 1995). They are able to bind 
to each subunit within the tetramer, therefore for every RyR, a maximum of four FKBP 
molecules can be bound (Wagenknecht et al., 1997). When FKBP dissociates from RyR, 
receptor gating is altered and changes in Ca2+ homeostasis are observed (Timerman et al., 1993; 
Cameron et al., 1995). 
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1.3.1 FKBP12 vs. FKBP12.6 
Previous studies demonstrated FKBP12.6 (calstabin2) to have a higher affinity for RyR2 in 
comparison to FKBP12 (calstabin1) in the heart (Guo et al., 2010 ). A study by Asghari et al. 
(2020) showed that there were modest differences between FKBP12 and FKBP12.6 in terms 
of RyR2 regulation and Ca2+ leak, with FKBP12.6 being able to reduce Ca2+ leak to a larger 
extent in comparison to FKBP12. Despite its high affinity for RyR2, other studies have shown 
that there is a greater expression of FKBP12 in comparison to FKBP12.6 in the heart 
(Jeyakumar et al., 2001). Currently, the abundance of FKBP12 and FKBP12.6 in relation to 
one another in the brain is unknown. 
 
1.3.2 FKBP regulation of Ca2+ leak in the brain 
As aforementioned, a lot of what is known about RyR2 and its ability to reduce Ca2+ leak has 
been derived from cardiac studies. Although previous studies identified the RyR2 isoform in 
hippocampal neurons to be like the “cardiac isoform”, there are a limited number of studies 
that look at FKBP12 and FKBP12.6, and their interactions with RyR2 in the brain.  
 
Those studies in the brain that have previously looked at the effects of FKBP12 and FKBP12.6 
on RyR2-mediated Ca2+ leak found similar findings to the heart. They noted that in the absence 
of FKBP12 or FKBP12.6, there were learning and memory deficits due to the increase in RyR2 
Ca2+ leak, with multiple studies concluding that the downregulation of FKBP12 and FKBP12.6 
expression resulted in age-related Ca2+ dyshomeostasis due to abnormal CICR in the brain 
(Gant et al., 2011; Gant et al., 2014; Han et al., 2020). Although this has been reiterated by 
many studies in the field, there have yet to be studies that examine the structural arrangement 
of RyR2 in neurons and its effect on Ca2+ leak. Much of what we know about RyR2 has been 
primarily derived from previous cardiac research. 
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1.3.3 Regulating Ca2+ leak in the heart 
In the heart, studies have shown that both FKBP12 and FKBP12.6 are able to reduce Ca2+ leak, 
resulting in tighter RyR2 clusters in a more organized arrangement (Figure 4). A closer 
comparison between FKBP12 and FKBP12.6 showed that FKBP12.6 had a larger impact on 
reducing Ca2+ leak than FKBP12 (Asghari et al., 2020). Asghari et al. (2020) suggested that 
this reduction in Ca2+ leak could be due to FKBP12.6 stabilizing the receptor, therefore 
reducing the mean cluster area, the number of channels per cluster, and more tightly packed 
channels within a cluster. Mutations in FKBP12.6 that increased its binding affinity for RyR2 
indicated that FKBP12.6 was able to reduce heart failure (HF), coming to the conclusion that 
by manipulating the relationship between FKBP12.6 and RyR2, they were able to restore RyR2 




Figure 1.4 Ca2+ leak in relation to RyR2 cluster arrangement. The less organized and more spaced out 
RYR2 clusters are, the larger the Ca2+ leak (left). The more organized and tightly packed clusters are together, 
the less Ca2+ leak there is (right). Image made via BioRender 
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1.3.4 FKBP12.6: a potential therapeutic target? 
Although both FKBP proteins have an effect on RyR2 that regulates CICR in both the heart 
and in the brain, it appears that FKBP12.6 regulates RyR2-mediated Ca2+ leak a lot more tightly 
in comparison to FKBP12 in the heart (Asghari et al., 2020). Gant et al. (2014) discovered the 
downregulation of both FKBP12 and FKBP12.6 in aging and early-stage AD 3-4 month old 
Fischer 344 rats, however the downregulation of FKBP12.6 was a lot more consistent, whereas 
FKBP12 downregulation was more variable. They suggested that FKBP12.6 could have a 
critical, functional role in AD development. From both cardiac and neuronal studies, we can 
consider FKBP12.6 as a potential therapeutic target to reduce the burden of pathophysiological 
lesions observed in AD patients.  
 
1.4 Targeting the RyR2-FKBP12.6 interaction: using S107 
Diagnosis of AD at an early stage is difficult as there are a large range of symptoms that 
individuals can exhibit, from psychosis and memory loss to depression and anxiety (Aalten et 
al., 2007; Eratne et al., 2018; Uddin et al., 2020). Moreover, current treatments are unable to 
tackle the progression of the disease. Instead, patients are presented with adverse effects when 
prescribed with AD medication (Uddin et al., 2020). 
 
A Rycal drug, S107,  is a 1,4-benzothiazepine derivative used to stabilize the RyR2-FKBP12.6 
interaction by preventing FKBP12.6 depletion, consequently reducing Ca2+ leak (Liu et al., 
2012; Bussiere et al., 2017). It has been shown that there are reduced FKBP12.6 levels in 
patients suffering from stress-induced cognitive dysfunction, therefore leading to a decrease in 
LTP. However, S107 treatment showed promising effects as it was able to rescue the decrease 
in LTP originally observed (Liu et al., 2012). A lot of recent studies have used S107 as a drug 
treatment that restores the presence of FKBP12.6 to reduce Ca2+ leak, emphasizing its 
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restorative effect (Mei et al., 2013; Kreko-Pierce et al., 2016; Bussiere et al., 2017; Dridi et al., 
2020). This has been demonstrated not only in AD models, but also in other neuropathological 
models such as Huntington’s disease (HD) (Kreko-Pierce et al., 2016; Dridi et al., 2020). 
However, whether S107 reduces Ca2+ leak in neurons by modifying RyR2 arrangement remains 
unknown. 
 
This highlights S107 as a potential therapeutic drug to treat patients with AD, as it has the 




RyR2 is an important Ca2+ release channel that is not only located in cardiomyocytes but also 
in neuronal cells in the brain. With the help of modulatory proteins such as FKBP12.6, they 
control the amount of Ca2+ being released from the ER to amplify the incoming Ca2+ signal 
from the action potential to allow the release of neurotransmitters at the synaptic cleft. In the 
absence of FKBP12.6, we see an increase in Ca2+ leak out of RyR2, thus resulting in altered 
synaptic transmission and the development of AD-like symptoms in patients. Whilst many 
studies have explored RyR2 as a potential therapeutic target, more recent studies have begun 
considering FKBP12.6 as a potential therapeutic target. S107, a Rycal drug, has been 
introduced as a form of treatment that can prevent FKBP12.6 depletion by stabilizing the 
RyR2-FKBP12.6 complex. Despite most studies providing this fact, there have yet to be studies 
that actually explore the mechanism of action of FKBP12.6 and whether it involves the 
structural arrangement of RyR2. 
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This project aimed to explore both the functional and structural changes of RyR2 observed 
under S107 treatment. As proof of principle, this study used  in HEK293 cells, an easily 
manipulated cell line, which has been used extensively to study the function of RyR2  (Jiang 
et al., 2005; Kong et al., 2007; Xiao et al., 2007; Waddell et al., 2016). I hypothesized that co-
expression of FKBP12.6 in HEK293 cells expressing RyR2 would reduce Ca2+ leak, due to the 
formation of more organized RyR2 clusters as a consequence of tighter and smaller clusters 
forming (RyR2 count). Additionally, I hypothesized that the addition of S107 would further 
reduce Ca2+ leak, due to an enhanced interaction between RyR2 and FKBP12.6, creating even 
more organized RyR2 clusters. I expected to see no change in the distribution of RyR2 (spread) 
across the area of a cell, as FKBP12.6 should not have an effect on RyR2 clusters but rather 




2.1 Cell culture 
2.1.1 HEK293 cell preparation 
A stable tetracycline inducible HEK293-RyR2 expressing cell line, provided by Professor 
Wayne Chen (University of Calgary, Canada), was cryopreserved at -80°C  in 1 mL aliquots in 
Dulbecco’s modified eagle medium (DMEM: 25 mM D-glucose, 1.8 mM CaCl2, 4 mM L-
glutamine, 5.3 mM KCl, 110 mM NaCl, 0.8 mM MgSO4, 44 mM NaHCO2, 0.9 mM NaH2PO-
H2O; pH 7.4) (Life Technologies) enriched with 1% non-essential amino acids (NEAA) (Life 
Technologies), 10% foetal bovine serum (FBS) (Sigma Aldrich), 1% penicillin and 1% 
streptomycin (Thermo Fisher) plus 10% dimethyl sulfoxide (DMSO) (Jiang et al., 2004). Cells 
were thawed and placed in a humidified incubator for 24 hours at 37°C with 5% O2. They were 
subsequently replenished with fresh pre-warmed DMEM and left in the incubator until they 
reached ~90% confluence, ready for subculture.  
 
2.1.2 HEK293 subculture 
Cells were subcultured into 25cm2 or 75cm2 flasks. Once at ~90% confluence, cells were 
washed twice with 2 mL or 5 mL phosphate-buffered saline (PBS: 2.7 mM KCl, 137 mM NaCl, 
1.8 mM KH2PO), 1 mL or 3 mL PBS and placed in the incubator for 5 minutes. To dislodge 
the cells from the interior of the flask, the cells were agitated before adding 6.5 mL DMEM to 
a 25 cm2 flask to make up an overall volume of 7.5 mL, or 17 mL DMEM to a 75 cm2 flask to 
make up an overall volume of 20 mL. The cells were pipetted up and down three times to create 
a homogenous mixture of cells before being split into subsequent flasks. These were left for up 
to 3 days to grow and proliferate before using for single-cell imaging. HEK293 cells were kept 
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up to a passage of nine before being discarded, as previous studies have shown that cell health 
deteriorates as passage number increases (Thomas & Smart, 2005). 
 
2.1.3 Plating cells in 6-well cell culture plates 
Cells were grown on 13 mm coverslips sterilized in 70% ethanol and placed in 6-well cell 
culture plates. The coverslips were covered in poly-L-lysine (Sigma) for ~ 10 minutes to ensure 
that HEK293 cells would be able to adhere to the surface of the coverslips, vacuumed off and 
submerged in 2 mL DMEM. 1 mL of subculture cell mix was put with 6 mL DMEM (1:6 
dilution), and this mixture was pipetted in a spiral motion in each well for even distribution.  
 
2.1.4 cDNA transfection 
Using the calcium phosphate-precipitation method, cells were transfected either with  
FKBP12.6 or with a mock transfection (mix excluding FKBP12.6 cDNA) 24 hours after plating 
(Graham & van der Eb, 1973). Under the laminar hood, a CaCl2-cDNA mixture was produced 
per condition and added to 2x HEPES in a dropwise manner, shaking to ensure that there was 
an even distribution of cDNA in the transfection mix. 
 
 
Table 1 Components of FKBP12.6 cDNA transfection mix. 
Ingredient Concentration 
2x HEPES (pH 7.05) 
274 mM NaCl, 55 mM HEPES, 1.75 mM 
Na2HPO4⋅7H2O 
CaCl2 2 M 
MilliQ H2O  
cDNA, FKBP12.6 5 µg 
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2.1.5 Induction of RyR2WT expression 
Tetracycline was used to induce the expression of RyR2 in RyR2WT-HEK293 cells (Kong et 
al., 2007). Sixteen hours after transfection, the growth medium was replaced with fresh DMEM 
twice to ensure the removal of waste products discarded by the cells. To induce the expression 
of RyR2, 3 mL DMEM was added containing 0.1 µg/mL tetracycline to each well. This enables 
cells to be used for cytosolic Ca2+ imaging.  
 
2.2 Cell health 
Cells were monitored on a regular basis under an inverted microscope (Olympus CKX41) to 
observe confluence and cell health. A few months into my project, I began to notice changes 
in cell health. 
 
2.2.1 Healthy cells 
 
Figure 2.1 Microscope images taken using Olympus CKX41 of healthy HEK293 cells. (A) HEK293 cells on 
Day 2, showing approximately 75% confluence at 10x magnification. (B) HEK293 cells on Day 3, showing 
approximately 90% confluence at 4x magnification. Scalebar for all images is 50µm. 
 
Previous studies have noted that cell morphology and growth rate are good indicators of cell 





rounded, but are oval in shape and have filopodia-like structures extending out from the cell 
body. By Day 3, we expect to see cell growth at approximately 90% confluence. In addition, 
the DMEM-based medium the cells are grown in should be clear and orange in color.  
 
2.2.2 Cell contamination 
On the contrary, Figure 2.2 shows examples of cellular contamination. Cells in Figure 2.2A are 
more rounded and circular in shape. It is also evident that there are less filopodia-like structures 
extending from cell bodies. By Day 3 (Figure 2.2A), we can see there is a clear reduction in 
cell growth compared to the similar timepoint in the healthy cells shown above (Figure 2.1B).  
 
Figure 2.2 Microscope images taken using Olympus CKX41 of contaminated HEK293 cells. (A) HEK293 
cells on Day 3. (B) Contaminated FKBP12.6 cDNA in transfection mix growing in DMEM. Scalebar for all 
images is 50µm. 
 
As shown in Figure 2.2, the floating brown debris are an indication of cellular contamination, 
as they affect the growth of healthy HEK293 cells, and therefore we see a visible reduction in 
cell growth. In addition, cellular contamination showed a cloudy appearance and change in 
color of the DMEM media the cells were cultured in. It is also visible in Figure 2.2 that there 







It was deduced that the cellular contamination could be due to a multitude of reasons: coverslips 
that were not fully sterilized, contaminated cDNA, or contaminated solutions used for 
transfection. To identify the source of contamination, I performed several trials. To investigate 
whether the cDNA was contaminated, I performed a mock transfection and a cDNA 
transfection in a 6-well plate with only DMEM.  
 
In order to overcome this, I adjusted my sterilizing technique of the coverslips to ensure they 
had minimal contact with other surfaces other than the 6-well cell culture plate they would be 
placed in. Furthermore, centrifuge tubes containing contaminated cDNA were sterilized with 
ethanol and filtered, whilst transfection solutions were either re-autoclaved or filtered. These 
methods seemed to help and prevent any further contamination. 
 
2.3 Functional assay: Ca2+ cytosolic measures 
Cytosolic Ca2+ measurements were performed between 14-21 hours after RyR2 induction. 
Cells were loaded with Fura-2 AM, a ratiometric dye dissolved in 12% pluronic acid in DMSO, 
plus 1  mg/mL bovine serum albumin (BSA) and 2 µM of Fura-2 AM. After a 10 minute 
incubation period, the cells were washed with Kreb’s-Ringer HEPES (KRH) (125 mM NaCl, 
25 mM HEPES, 12.5 mM D-Glucose, 5 mM KCl, 1.2 mM MgCl2) for another 10 minutes to 
remove unloaded dye to allow for de-esterification. During imaging, cells were illuminated at 
340 nm and 380 nm using a LED light source (pE300). Fluorescence was captured through a 
510 nm longpass filter by an Andor Zyla sCMOS camera, with a binning setting of 4x4 and an 
exposure of 200 ms. A ratiometric dye was used to minimize the artifact of loading level signal 
differences between cells. 
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2.3.1 Store-overload induced Ca2+ release (SOICR) 
To trigger excessive Ca2+ leak (SOICR) in HEK293RyR2 cells, cells were exposed to KRH-
containing increasing Ca2+ concentrations: 0 mM, 0.1 mM, 0.2 mM, 0.3 mM, 0.5 mM, and 1 
mM using a superperfusion system. Cells were first exposed to 0 mM for 2 minutes, whilst 
cells were exposed to the other concentrations for consecutive 4-minute intervals.  
 
2.3.2 Caffeine-induced Ca2+ release 
At the end of each experiment cells were exposed to 1 mM Ca2+ containing 20 mM caffeine 
for 2 minutes to trigger the release of Ca2+ by reducing the luminal threshold of SOICR (Kong 
et al., 2008). This step was to confirm the expression of caffeine-sensitive RyR2 in each cell.  
 
2.4 Structural assay: structural arrangement of RyR2 
2.4.1 PFA fixation 
Eighteen hours after induction, cells were washed with PBS and fixed in 2% paraformaldehyde 
(PFA) for 5 minutes. They were subsequently washed and stored in PBS at 4°C. 
 
2.4.2 Immunocytochemistry 
After PFA fixation, Triton X-100 was used to permeabilize cells to be able to detect 
intracellular antigens by dissolving lipids in the cell membrane (Jamur & Oliver, 2010). The 
cells were permeabilized in Triton X-100 for 15 minutes and then put in a blocking buffer (2% 
BSA, 0.5% Triton X-100 in PBS) for 30 minutes at room temperature. This was followed by 
three washes in PBS before incubation with RyR2 C3.33 mouse primary antibody (1:100 
dilution) or an FKBP12.6 rabbit primary antibody (1:100 dilution) overnight at 4°C in a 
humidified environment to prevent cells from drying out. Cells were then washed in PBS before 
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incubation with an anti-rabbit secondary antibody for 555 nm (1:200 dilution) and anti-mouse 
secondary antibodies for 488 nm and 680 nm (1:200 dilution) for 2.5 hours at 4°C. 
 
2.4.3 Direct stochastic optical reconstruction microscopy (dSTORM) imaging 
Super-resolution dSTORM imaging was performed using an Olympus IX81 inverted 
microscope with a 60x oil-immersed 1.45 NA objective. The laser intensity of the super-
resolution microscope was set at ~300 mW. Up to 20,000 frames were collected per cell, and 
3 cells were imaged per coverslip using PYMEAcquire and LaunchWorkers. The integration 
time was set to 50 ms, and was captured on an uEyE cMOS camera (Munro et al., 2021).  
 
2.4.4 Confocal imaging 
Images were captured using an inverted confocal microscope (Nikon A1), using a 40x 1.3 NA 
objective. Laser lines were set to 488nm and 560 nm for excitation, with pinhole set to 1 A.U. 
Images were collected on NIS AR 2.0 elements. Laser settings and gain were kept constant 
between images. 
 
2.5 Drug treatment 
2.5.1 Treatment with DMSO 
HEK293 cells were incubated in 10 µM DMSO with DMEM for 2-3 hours before single-cell 
imaging, as described earlier. During cytosolic Ca2+ measures, cells were constantly 
superperfused with Ca2+ solutions containing 10 µM DMSO. 
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2.5.2 Treatment with S107 
Cells were incubated in 10 µM S107 (Selleck) with DMEM for 2-3 hours before single-cell 
imaging. During cytosolic Ca2+ measures, cells were constantly perfused with Ca2+ solutions 
containing 10 µM S107 present. 
 
2.6 Data analysis 
Different treatment groups were blinded before analysis. 100 regions of interest (ROIs) were 
randomly selected from the field of view looking at caffeine responsive cells per coverslip. 
This is to ensure that cells that are ROIs express RyR2. Both SOICR occurrence and SOICR 
amplitude (relative to the caffeine mediated peak) were determined using NIS AR 2.0 Elements. 
Each ROI generated a trace showing the change in fluorescence over time as cells were excited 
at two wavelengths: 340 nm and 380 nm. The visible peaks were indicators of SOICR activity 
(Figure 2.4).  
 
Cells highlighted in Figure 2.3A and B are examples of cells that are unhealthy and do not fit 
the selection criteria of being ROIs during data analysis. These cells demonstrate unhealthy 
characteristics of HEK293 cells. The selection criteria for ROIs include cells that are healthy, 
exhibiting dendritic processes, are more oval-shaped, moderately sized, have a distinguishable 
cell outline, and are well-spaced amongst other neighboring HEK293 cells.  Figure 2.3A shows 
a perfectly rounded cell which lacks any dendritic features, commonly exhibited in a healthy 
HEK293 cell. Furthermore, it is relatively small in size in comparison to its surrounding cells, 
suggesting it may undergo apoptosis. Moreover, Figure 2.3B shows a cluster of HEK293 cells 
together. Here, the outline of any of these cells are indistinguishable, and they collectively 
register as an individual Ca2+ release unit during cytosolic Ca2+ imaging, thus are not 
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representative of a single cell. In contrast, cells C and D are examples of the type of cells 




Figure 2.3 Field of view of active HEK293 cells under caffeine exposure. (A) Rounded, small, and unhealthy 
cell. (B) Indistinguishable cell outline. (C & D) Oval-shaped cells with spinous processes coming out of them and 
a discernible cell outline. 
 
 
Figure 2.4 Example trace of a single cell during cytosolic Ca2+ imaging. SOICR events represented as peaks 








2.6.1  Ca2+ cytosolic measures: occurrence of SOICR events 
Peak occurrence represents the concentration at which a cell first becomes active and 
demonstrates SOICR activity and is an indication of the susceptibility of the cell to SOICR. 
The Ca2+ concentration at which the first peak first appeared was recorded (Figure 2.5) and the 
percentage of cells first experiencing SOICR in each Ca2+ concentration was plotted. Cells that 
expressed RyR2 only were used as controls in comparison to other treatment groups. 
 
 
Figure 2.5 Example trace of SOICR events and identification of SOICR occurrence at a specific 
concentration. Cells are exposed to increasing Ca2+ concentrations and caffeine at 2-4 minute intervals. SOICR 
activity first occurs at 0.3 mM in this example. 
 
2.6.2  Ca2+ cytosolic measures: SOICR amplitude 
Peak amplitude was used to determine the amount of Ca2+ that was released by cells during 
each SOICR event and was measured using NIS AR 2.0 Elements. The amplitude of caffeine 
was measured, and the amplitude of peaks at increasing Ca2+ concentrations were averaged. 
The baseline value for each cell recording was subtracted from the average amplitude generated 
from SOICR events before caffeine-induced release and subtracted from the amplitude of 
caffeine-induced SOICR. This assumes that during the addition of caffeine, all Ca2+ stores are 
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depleted, thus the value obtained from the caffeine peak determines the maximal amount of 
Ca2+ within the stores. This gives us an indication as to how much of the Ca2+ store is depleted 
prior to the addition of caffeine at increasing Ca2+ concentrations. Cells that expressed RyR2 




Figure 2.6 Example trace of SOICR events and identification of amplitude of SOICR. Cells are exposed to 
increasing Ca2+ concentrations and caffeine at 2-4 minute intervals. 
 
2.6.3 Structural assay: dSTORM imaging 
Using PYMEAcquire, the threshold of cell activity was set to a minimum of 1.5 and the 
background ratio was set to 0:30. This is to ensure that the program was not picking up any 
background noise or activity that was not present during the time. Outlines of cells were traced 
using ImageJ to create a mask. The mask ensures that any fluorescent events that occur outside 
of the cell are eliminated during analysis and only considers fluorescent events within the 
boundary of the cell. The area of each RyR2 cluster, the area of the overall cell, and raw 
intensity density were calculated and generated by the software using a Python script. The area 
of each RyR2 cluster was used to determine the average size of RyR2 clusters. From this, RyR2 
count was calculated dividing the average RyR2 cluster size divided by the single size of an 
SOICR 
peak size 
caffeine peak size 
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RyR2 channel (0.0009). To calculate RyR2 spread, the area of each RyR2 cluster was counted 
and divided by the total area of the cell. RyR2 packing (termed “density”) was determined by 
diving the raw intensity density by the area of each RyR2 cluster, and the average of this value 
to give an arbitrary unit. 
 
2.6.4 Statistical analysis 
GraphPad Prism was used to perform one-way ANOVA (for the magnitude of SOICR) and 
two-way ANOVA (for SOICR activity) with Dunnett’s post hoc test as a multiple comparisons. 
Student two-tailed unpaired t-tests were performed to determine statistical significance 
between treatment groups when measuring RyR2 count, spread, and density. A Shapiro-Wilk’s 
test was performed to ensure data normality before performing the parametric statistical 





The aim of this project was to determine the changes in RyR2 function and structure in 
response to FKBP12.6 and S107 treatment in HEK293 cells. Experiments were conducted in 
the HEK293 cell model as HEK293 cells do not naturally express RyR2 or FKBP12.6 (Thomas 
& Smart, 2005). This makes it easy to study these proteins independently in comparison to 
neurons, where testing the proteins independently is a lot harder to do and usually involves 
knockout models (Jiang et al., 2004; Yuan et al., 2016). From this, it ensures that any effects 
observed are due to the function of RyR2 and FKBP12.6 instead of other changes in signalling. 
 
A functional Ca2+ assay was performed to explore changes in RyR2-mediated Ca2+ leak in 
response to increasing extracellular Ca2+ concentrations, mimicking abnormal Ca2+ leak 
(SOICR) events (Section 3.1). The first occurrence a SOICR event was analyzed to calculate 
the Ca2+ concentration required to elicit SOICR and if this was different between groups 
(Section 3.1.1). The magnitude of Ca2+ release per SOICR event was also determined under 
each condition (Section 3.1.2). It was hypothesized that there would be a reduction in Ca2+ 
leak in the presence of FKBP12.6; therefore there would be less and smaller SOIR events at 
any given Ca2+ concentration. It was also hypothesized that the addition of S107 would further 
reduce the magnitude and occurrence of SOICR events.  
 
Subsequently, a structural assay was performed to investigate if any changes observed in the 
function of RyR2 were due to changes in RyR2 arrangement (Section 3.2). 
Immunocytochemistry was performed to confirm the presence of RyR2 and FKBP12.6 
(Section 3.2.1), ensuring that any changes observed were due to the presence or absence of 
these proteins. Following this, super-resolution microscopy was used to view individual RyR2 
clusters and their structural parameters were determined (Section 3.2.2). It was hypothesized 
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that when cells are treated FKBP12.6 and S107, RyR2 would be more densely and tightly 
packed, causing an apparent reduction in the size of RyR2 clusters. However, RyR2 




3.1 Functional assay: Ca2+ cytosolic measurements 
3.1.1 Effect of FKBP12.6 and S107 on the percentage of SOICR events 
occurring in HEK293 cells 
To determine the effect of FKBP12.6 and S107 on the occurrence of SOICR, single cell Ca2+ 
imaging was performed in HEK293 cells expressing RyR2. Figures 3.1-3.4 show 
representative snapshots of Fura-2 loaded cells at different Ca2+ concentrations (0.1 mM, 0.2 
mM, 0.3 mM, 0.5 mM, 1 mM, 1 mM + caffeine). Figure 3.1 represents RyR2-only, Figure 3.2 
represents RyR2 + FKBP12.6, Figure 3.3 represents RyR2 + FKBP12.6 + S107, and Figure 
3.4 represents RyR2 + S107. In the false color images, increased cytosolic Ca2+ (a SOICR event) 
is shown as green/red. As observed, when exposed to higher Ca2+ concentrations, more cells 
appear to experience SOICR events in all treatment groups (Figure 3.1A, where we see 
approximately 4 cells active vs. Figure 3.1E, where we see over 40 cells active) . As 
extracellular Ca2+ concentrations increase, there appears to be a reduction in the number of 
SOICR events in cells co-expressing FKBP12.6 with or without S107 treatment (Figure 3.2E, 
where we see approximately over 25 cells active vs. Figure 3.3E, where we see approximately 
15 cells active ). 
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Figure 3.1 SOICR activity in HEK293 cells in Fura-2 AM ratiometric dye (A-F) in RyR2 only cells. Cells 
are exposed to increasing Ca2+ concentrations:  (A) 0.1 mM Ca2+ (B) 0.2 mM Ca2+ (C) 0.3 mM Ca2+ (D) 0.5 mM 
Ca2+ (E) 1 mM Ca2+ (F) 1 mM Ca2+ + caffeine. Scalebar for all images is 200µm. 
 
Figure 3.2 SOICR activity in HEK293 cells in Fura-2 AM ratiometric dye (A-F) in RyR2 + FKBP12.6 cells. 
Cells are exposed to increasing Ca2+ concentrations:  (A) 0.1 mM Ca2+ (B) 0.2 mM Ca2+ (C) 0.3 mM Ca2+ (D) 0.5 
mM Ca2+ (E) 1 mM Ca2+ (F) 1 mM Ca2+ + caffeine. Scalebar for all images is 200µm. 
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Figure 3.3 SOICR activity in HEK293 cells in Fura-2 AM ratiometric dye (A-F) in RyR2 + FKBP12.6 + 
S107 cells. Cells are exposed to increasing Ca2+ concentrations:  (A) 0.1 mM Ca2+ (B) 0.2 mM Ca2+ (C) 0.3 mM 
Ca2+ (D) 0.5 mM Ca2+ (E) 1 mM Ca2+ (F) 1 mM Ca2+ + caffeine. Scalebar for all images is 200µm. 
 
Figure 3.4 SOICR activity in HEK293 cells in Fura-2 AM ratiometric dye (A-F) in RyR2 + S107 cells. Cells 
are exposed to increasing Ca2+ concentrations:  (A) 0.1 mM Ca2+ (B) 0.2 mM Ca2+ (C) 0.3 mM Ca2+ (D) 0.5 mM 
Ca2+ (E) 1 mM Ca2+ (F) 1 mM Ca2+ + caffeine. Scalebar for all images is 200µm. 
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Analyzing these data using two-way ANOVA showed that at low extracellular Ca2+ 
concentrations (0 mM, 0.1 mM, and 0.2 mM), there was no significant difference (p>0.05) 
between any of the treatment groups compared to cells expressing RyR2 alone. However, at 
higher Ca2+ concentrations, the co-expression of FKBP12.6 reduced SOICR. At 0.3 mM Ca2+, 
34.78 ± 5.497% of RyR2-only (control) cells experienced SOICR events compared to only 
20.15 ± 3.94% (p<0.01) of cells expressing RyR2 and FKBP12.6, an approximate 1.7-fold 
reduction in SOICR activity. A similar effect was also observed at 0.5 mM Ca2+ and 1 mM 
Ca2+, where 61 ± 4.05% and 64.44 ± 3.46% of RyR2-only expressing cells experienced SOICR 
respectively, which was significantly reduced in cells co-expressing FKBP12.6, where the 
mean number of SOICR events at the same Ca2+ concentrations were reduced to 42.16 ± 4.09% 
and 61.94 ± 3.26% respectively (p<0.05) (Figure 3.5). At 0.5 mM and 1 mM Ca2+, this 
represents a 1.45-fold and 1.05 fold reduction in SOICR activity. This indicates that FKBP12.6 
is able to reduce the propensity for SOICR. 
 
With cells containing FKBP12.6 and S107, at 0.3 mM Ca2+, RyR2 treated with both FKBP12.6 
and S107 had a significant reduction in the mean number SOICR events (p<0.05) compared to 
the control, with only 23.25 ± 3.06% of cells experiencing SOICR events, equating to a 1.5-
fold reduction in SOICR activity compared to RyR2 alone. A similar reduction was also 
observed at 0.5 mM Ca2+ and 1 mM Ca2+, with 41 ± 3.64%, and 54.38 ± 3.91% respectively 
experiencing SOICR events compared to 61 ± 4.05% and 64.44 ± 3.46% for RyR2-only 
(p<0.001). In contrast to cells co-expressing FKBP12.6, S107 alone had no effect on the 
occurrence of SOICR at any Ca2+ concentration (p>0.05) (Figure 3.5). Combined, these data 
suggests that FKBP12.6, either alone or in combination with S107, is able to reduce the 







Figure 3.5 Example traces of SOICR events and percentage of cells experiencing SOICR events. (A) RyR2-
only cells (B) RyR2 + FKBP12.6 (C) RyR2 + FKBP12.6 + S107 (D) RyR2 + S107 (E) Percentage of cells with 
SOICR events at increasing extracellular Ca2+ concentrations: 0 mM, 0.1 mM, 0.2 mM, 0.3 mM, 0.5 mM, 1 mM. 
Treatment groups include RyR2, RyR2 + FKBP12.6, RyR2 + FKBP12.6 + S107, RyR2 + S107; n=9, 9, 8, 11 
respectively. Values are expressed as a mean ± SEM. # represents p<0.005 for RyR2 + FKBP12.6 vs. RyR2. * 






3.1.2 Amplitude of SOICR events 
To determine the effect of FKBP12.6 and S107 on the amplitude of SOICR events, the 
magnitude of change in Fura-2 fluorescence was determined for each SOICR event. The false 
color images, as shown in Figures 3.1-3.4, range from a spectrum of blue (little to no Ca2+ 
release), to green (moderate Ca2+ release), to red (large amount of Ca2+ release) as an indication 
of the degree of Ca2+ release during a SOICR event. As depicted in Figures 3.1-3.4F, there 
appears to be a difference between the amount of Ca2+ released each SOICR event between the 
different conditions. Comparing the treatments to RyR2-only cells (Figure 3.1F), cells co-
expressing FKBP12.6 only or treated only with S107 do not appear to have a difference in the 
magnitude of SOICR (Figures 3.2F and 3.3F). Figure 3.3F shows that at 1 mM Ca2+ and 
caffeine, there appears to be an overall reduction in the magnitude of SOICR when co-
expressing FKBP12.6 and treated with S107 in comparison to RyR2-only (Figure 3.1F).  
 
To determine if these observations were real differences, one-way ANOVA was used to 
compare the mean SOICR amplitude between each condition (Figure 3.6A-D). RyR2-only 
cells released 85.54 ± 1.26%  of their total Ca2+ store per SOICR event. Cells co-expressing 
FKBP12.6 showed no significant difference (p>0.05) in the relative release of Ca2+ per SOICR 
event, with 80.47 ± 1.38% of the total Ca2+ store released per SOICR event. However, cells 
treated with both FKBP12.6 and S107 had a 1.2 fold reduction in the magnitude of Ca2+ release 
to 72.66 ± 3.88% (p<0.001) of the total releasable store (Figure 3.6). Similarly, to cells co-
expressing FKBP12.6, RyR2 treated only with S107 showed no significant difference in 
comparison to RyR2-only (p>0.05).  From these results, it can be deduced that FKBP12.6 or 
S107 on its own does not affect the magnitude of SOICR. However, a combination of both 
FKBP12.6 and S107 is able to reduce the magnitude of SOICR. 
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Figure 3.6 Example traces of SOICR events and relative magnitude of SOICR events. (A) RyR2 only (B) 
RyR2 + FKBP12.6 (C) RyR2 + FKBP12.6 + S107 (D) RyR2 + S107 (E) relative magnitude of SOICR events   
from the following treatment groups: RyR2, RyR2 + FKBP12.6, RyR2 + S107, RyR2 + FKBP12.6 + S107; n=9, 
9, 8, 11 respectively. Values are a percentage of the total releasable Ca2+ store and are shown as a mean ± SEM. 





3.2 RyR2 arrangement 
The following sections were significantly delayed due to COVID and therefore are more 
preliminary in nature. Much of the methodology would need further optimization to obtain 
high quality, quantifiable data. 
 
3.2.1 Immunolabelling RyR2 and FKBP12.6 
Immunolabelling for RyR2 and FKBP12.6 was used to determine the presence or absence of 
both proteins under different treatment conditions. Figures 3.7 and 3.8 are examples of 
HEK293 RyR2 cells with or without FKBP12.6 and S107 treatment. In RyR2-only cells, co-
labelling for RyR2 and FKBP12.6 show that whilst there is RyR2 present in the cell, there is 
no FKBP12.6 present (Figure 3.7). In contrast, immunolabelling in RyR2 cells co-expressing 
FKBP12.6 and treated with S107 shows an abundance of RyR2 and FKBP12.6 present in the 
cell (Figure 3.8). A merged image of the two shows some overlap between FKBP12.6 and 
RyR2, suggesting colocalization of the two proteins. This confirms that non-transfected RyR2-
only cells do not contain endogenous FKBP12.6 and that the FKBP12.6 cDNA transfection 
was successful. It must be noted that these data are from a single experiment, and the health of 
the cells and quality of labelling was not optimal. Whilst these data support the cell model used, 
any extensive interpretation should be performed with caution. 
 
Figure 3.9 shows a lower magnification image of cells co-expressing RyR2 and FKBP12.6. 
The abundance of FKBP12.6 labelling(Figure 3.9C) indicates that majority of transfected 
HEK293 cells express FKBP12.6 and it co-localizes with RyR2. Although this is, again, a 
single experiment with sub-optimal labelling, it suggests that the functional changes observed 
in FKBP12.6-expressing cells (Section 3.1) are due to the presence of FKBP12.6 in most cells. 
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Due to the poor labelling and relatively high background for FKBP12.6, no quantification was 
performed to determine the efficiency of transfection. 
 
 
Figure 3.7 Immunocytochemistry labelling of RyR2 and FKBP12.6 of RyR2 cells-only under an inverted 
confocal microscope. (A) Staining of RyR2 using 488 nm antibody (B) Staining of FKBP12.6 using 568 nm 
antibody (C) Merge of RyR2 and FKBP12.6. Image brightness adjusted for display purposes. Scalebar for all 
images is 10µm. 
 
 
Figure 3.8 Immunocytochemistry labelling of RyR2 and FKBP12.6 of RyR2 cells co-expressing FKBP12.6 
and treated with S107 under an inverted confocal microscope. (A) Staining of RyR2 using 488 nm antibody 
(B) Staining of FKBP12.6 using 568 nm antibody (C) Merge of RyR2 and FKBP12.6. Image brightness adjusted 
for display purposes. Scalebar for all images is 10µm. 
 
 
Figure 3.9 Immunocytochemistry labelling of RyR2 and FKBP12.6 under an inverted confocal microscope. 
(A) Staining of RyR2 using 488 nm antibody (B) Staining of FKBP12.6 using 568 nm antibody (C) Merge of 
RyR2 and FKBP12.6. Image brightness adjusted for display purposes. Scalebar for all images is 10µm.  
A B C 
A B C 
A B C 
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3.2.2 dSTORM imaging 
dSTORM imaging is able to determine the position of a single fluorophore through excitation 
by a 680nm laser. Molecules become activated and bleached over time as they become exposed 
to the wavelength of the laser, and this process is repeated many times to eventually produce a 
super-resolution image that is able to pinpoint individual positions of molecules based on their 
fluorescent events. 
 
Figure 10 shows representative dSTORM images from cells expressing RyR2 alone or RyR2 
+ FKBP12.6 + S107. Time limited the time available for dSTORM experiments so only these 




Figure 3.10 dSTORM images of RyR2 clusters in HEK293 RyR2WT-expressing cells with (A) RyR2 only 
and (B) RyR2 and FKBP12.6 cells treated with S107. Each white dot represents an individual RyR2 cluster. 




Based on these images, RyR2 cluster size, channel packing (also termed as “density”) and 
spread were determined (Figure 3.11). RyR2 count is an indicator of the number of channels 
that are theoretically found within a cluster, whilst RyR2 spread refers to the distribution of 
RyR2 channel clusters across the area of the cell. RyR2 density uses the mean average size in 
relation to the raw intensity of the fluorophores to determine how tightly packed RyR2 channels 
are within each cell. An unpaired two-tailed student t-test was used to determine if there was a 
significant difference in RyR2 count, RyR2 spread, and RyR2 density between RyR2-only cells 
and RyR2 cells with FKBP12.6 and S107.  
 
RyR2 count shows that RyR2-only cells had a mean number of  21.24 ± 3.47 channels within 
a cluster, whereas RyR2 cells with both FKBP12.6 and S107 have a mean number of 17.62 ±  
4.62 channels per cluster. Despite an apparent 1.2 fold reduction in RyR2 count, this difference 
was not statistically significant (p>0.05) (Figure 3.11A). This indicates that the number of 
RyR2 channels per cluster is not affected upon the presence of FKBP12.6 and S107. Similarly, 
RyR2 spread did not show any significant difference (p>0.05) between RyR2-only cells and 
RyR2 cells with FKBP12.6 and S107. RyR2 cells with FKBP12.6 and S107 had 3.63 ± 0.52 
clusters per µm2, which was not different to RyR2-only cells, which had 3.54 ± 0.46 clusters 
per µm2 (Figure 3.11B). From these data, the distribution of RyR2 channels across the area of 
a cell is unchanged in the presence of FKBP12.6 and S107. Results from RyR2 density showed 
that RyR2-only cells had a mean density of 6.32 ×107 ± 9.82 ×106 arbitrary units, whilst RyR2 
with FKBP12.6 and S107 had a mean density of  9.98 ×107 ± 3.83 ×107 arbitrary units (Figure 
3.11C). Despite the apparent 1.6-fold increase in density of RyR2 channels in cells with 
FKBP12.6 and S107, this increase was not deemed statistically significant (p>0.05). This is 
likely due to the low number of cells able to be analyzed. This suggests that there is no 
difference in how tightly packed RyR2 channels are within clusters between RyR2 and RyR2 






Figure 3.11 RyR2 clusters with or without FKBP12.6 and S107 and their effect on (A) RyR2 count (B) 





Patients diagnosed with AD suffer from memory and cognitive deficits. Whilst the amyloid 
hypothesis has been widely explored as a theory to explain the development of AD in 
individuals, others have begun exploring the Ca2+ hypothesis. The Ca2+ hypothesis proposes 
that changes in Ca2+ homeostasis result in the formation of AD lesions that lead to the 
development of AD. RyR2, a homotetrameric protein receptor commonly found in the heart, 
has also been located in the CA1 hippocampal region, with more recent studies proposing its 
potential role in the Ca2+ dyshomeostasis observed in AD patients. Studies have begun looking 
at RyR2 modulators as potential therapeutic targets of AD. One such modulator is FKBP12.6, 
which regulates RyR2 by stabilizing the receptor to reduce Ca2+ leak. Despite its large 
prevalence within the NZ population, current treatment of AD is scarce, with current treatments 
having a minimal effect on symptoms experienced by AD patients. A Rycal drug, S107, has 
recently come to light as a potential therapeutic target, with many studies claiming that it 
prevents FKBP12.6 depletion and thus, reduces Ca2+ leak out of RyR2. However, there is a 
lack of studies that explore how S107 may alter the structural arrangement of RyR2 to achieve 
its function. 
 
Thus, the aim of this study was to explore the changes in RyR2 Ca2+ leak and its structural 
arrangement in response to FKBP12.6 and S107. It was hypothesized that in the presence of 
FKBP12.6, Ca2+ leak would be reduced, and therefore less and smaller SOICR events would 
be observed at any Ca2+ concentration. It was also hypothesized that treating cells with S107 
and FKBP12.6 would cause RyR2 to form more tightly packed and smaller clusters underlying 
their resistance to SOICR. To study this, single-cell Ca2+ imaging was performed to measure 
changes in SOICR activity and the magnitude of SOICR in cells expressing RyR2 alone, cells 
co-expressing FKBP12.6, cells treated with S107, and cells with a combination of FKBP12.6 
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co-expression and S107 treatment (Section 3.1). The expression of FKBP12.6 and RyR2 in 
HEK293 cells were confirmed using immunocytochemistry. Lastly, dSTORM imaging was 
performed to examine any changes in the arrangement of RyR2 clusters (Section 3.2). 
 
4.1 Alterations in Ca2+ leak 
This study investigated the effect of FKBP12.6, S107, and a combination of the two on 
abnormal Ca2+ leak (SOICR) activity (Section 3.1.1) and the magnitude of SOICR (Section 
3.1.2) in RyR2-expressing cells using Fura-2AM cytosolic Ca2+ imaging.  
 
4.1.1 FKBP12.6 and its effect on SOICR  
Fura-2AM imaging showed that between RyR2-only cells and cells co-expressing FKBP12.6, 
there was a reduction in the number of SOICR events as extracellular Ca2+ concentrations 
increased (Figure 5). Specifically, there was a significant reduction in SOICR activity at higher 
extracellular Ca2+ concentrations (0.3 mm, 0.5 mM, and 1 mM Ca2+), suggesting that 
FKBP12.6 alone is able to reduce SOICR activity. The finding that FKBP12.6 reduced SOICR 
only at higher Ca2+ concentrations is consistent with the mechanism of SOICR. At lower Ca2+ 
concentrations, it is likely that the threshold for SOICR was not reached in most cells making 
the stabilizing effect of FKBP12.6 difficult to observe. However, as the extracellular Ca2+ 
concentration increased, this would lead to an increase in store luminal Ca2+, making SOICR 
more likely. Here, the more stabilized RyR2 with FKBP12.6 would have a higher threshold, 
making SOICR less likely. However, surprisingly, despite its ability to reduce the mean number 
of SOICR events occurring, FKBP12.6 did not demonstrate an effect on the magnitude of 
SOICR. Therefore, my hypothesis was partially supported as FKBP12.6 reduced the 
occurrence but not magnitude of SOICR. 
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FKBP12.6 has shown to reduce Ca2+ leak in cardiomyocytes (Liu et al., 2011). Liu et al. (2011) 
noted that their FKBP12.6-/- mice (FKBP12.6 knockout) showed an increase in Ca2+ sparks in 
comparison to their wild-type (control) model. However, their transgenic model that over-
expressed FKBP12.6 showed no significant difference in Ca2+ sparks in comparison to their 
WT model. Many other studies have demonstrated that FKBP12.6 shows a reduction in the 
propensity of SOICR by limiting the open probability (Po) of RyR2 in the heart(Prestle et al., 
2001; Xin et al., 2002; Gómez et al., 2004; Guo et al., 2010; Zhang et al., 2016). Yao et al. 
(2020) discovered that limiting the open time of RyR2 prevents neuronal hyperactivity, as well 
as AD-like deficits. An AD-related study involving CA1 hippocampal neurons also confirmed 
that deletion of FKBP12.6 resulted in an increase of SOICR events (Yuan et al., 2016). 
Moreover, Gant et al. (2011) found that FKBP12.6 was downregulated in aging rats, and that 
the dissociation of FKBP12.6 from RyR2 resulted in an increase in CICR, therefore 
recapitulating the aging phenotype in rats (Gant et al., 2011; Gant et al., 2014). The increase 
in Ca2+ leak has been linked to the decline of certain cognitive functions (Liu et al., 2012). As 
there is FKBP12.6 present, this stabilizes RyR2 and reduces it open probability. As a result, 
there is less Ca2+ being extruded from RyR2, and therefore there is a reduction in the number 
of neighboring RyR2 channels within a cluster that become activated. Consequently, SOICR 
activity decreases due to the reduction in the number of channels being activated. Although it 
is altering the open probability, it is not altering the amount of Ca2+ that is released from each 
RyR2, therefore SOICR magnitude remains unchanged. This could explain why I found a 
reduction in the occurrence and not the magnitude of SOICR in this study. Overall, these 
studies support both my hypothesis and my findings. This strengthens the idea that FKBP12.6 
could be a potential therapeutic target to treat AD-like symptoms that are observed with 
increased Ca2+ leak. 
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In contrast, Xiao et al. (2007) did not find a difference in the activation of RyR2 when 
FKBP12.6 was removed. Instead, they saw that the propensity of SOICR remained the same in 
HEK293RyR2 cells co-expressing FKBP12.6 in comparison to RyR2-only cells. Although 
they also performed Fura-2AM imaging on HEK293 cells, their cells were induced with 
tetracycline 24 to 30 hours prior to imaging. In contrast, this project induced cells 14 to 22 
hours prior to imaging. The difference in timing could be a reason as to why Xiao et al. (2007) 
did not see any differences in SOICR events with cells co-expressing FKBP12.6. (Jordan et al., 
1996) and (Guo et al., 2017) have shown that cells exhibit the highest transfection efficiency 
when incubated for shorter periods of time. Over incubation of transfection mixture can lead 
to cell damage due to toxicity, and therefore reduce transfection efficiency. 
 
Moreover, a CPVT study conducted by George et al. (2003) also noted that the observed SR 
Ca2+ leak in their CPVT RyR2 mutation models were independent of FKBP12.6, seeing no 
discernible difference against their WT control. The differences observed could be due to the 
fact that cardiomyocytes express a low percentage of FKBP12.6, and FKBP12 is 
predominantly found in cardiomyocytes instead (Jeyakumar et al., 2001). Thus, the small 
amount of FKBP12.6 in cardiomyocytes could have little to no effect on RyR2, hence it could 
explain why George et al. (2003) did not see a difference in the propensity of SOICR with 
FKBP12.6 present. Other studies have proposed that FKBP12.6 poses no effect on RyR2-
mediated Ca2+ release (Hunt et al., 2007).  
 
4.1.2 The effect of FKBP12.6 and S107 on SOICR 
In conjunction with cells co-expressing FKBP12.6, cells were also treated with S107 to 
investigate the combined effect on Ca2+ leak. S107 is a Rycal drug that stabilizes RyR2 by 
preventing FKBP12.6 depletion to reduce RyR2-mediated Ca2+ leak. Statistical analysis using 
two-way ANOVA showed that there was a significant reduction in both SOICR activity and 
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magnitude of SOICR in cells co-expressing FKBP12.6 and treated with S107 in comparison to 
RyR2-only cells (Figure 6). However, further statistical comparison between cells co-
expressing RyR2 and FKBP12.6, and cells with both FKBP12.6 and S107 show that there is 
no difference (p>0.05) between them. Combined with the data above, this data could suggest 
that FKBP12.6 has a minimal effect on RyR2 in terms of the magnitude of SOICR in the 
absence of S107. However, the addition of S107 ensures that FKBP12.6 will interact with 
RyR2 more tightly and this closer interaction is then able to not only reduce the occurrence, 
but also the magnitude of SOICR. Cardiac studies such as (Shan et al., 2012) have explored 
the effect of S107 on the atrial myocytes. Their findings highlighted that treatment of S107 
reduced diastolic SR Ca2+ leak (SOICR) in atrial myocytes, noting that they saw an overall 
reduction in total Ca2+ leak and a reduction in SR Ca2+ load (∆F/F0) in comparison to untreated 
cells. Studies modelling AD have shown that S107 treatment results in reduced RyR2-mediated 
Ca2+ leak, improving synaptic plasticity and cognitive function (Bussiere et al., 2017; 
Lacampagne et al., 2017). Overall, both studies in the heart and brain confirm that S107 works 
with FKBP12.6 to reduce RyR2-mediated Ca2+ leak, reducing the number of SOICR events as 
well as the magnitude of SOICR, in agreement with my findings. This could indicate S107 as 
a potential therapeutic drug to treat AD-like symptoms. 
 
4.1.3 The effect of S107 alone on SOICR 
As there were observed changes in SOICR activity and magnitude between RyR2-only cells, 
and cells co-expressing FKBP12.6 and treated with S107, I wanted to determine if S107 
worked via FKBP12.6 or had a direct effect on SOICR activity and magnitude. The cytosolic 
Ca2+ imaging results indicate that there was no significant difference in SOICR activity or the 
magnitude of SOICR between RyR2-only cells and RyR2 cells treated with S107. This 
supports the hypothesis that S107 does not influence Ca2+ leak on its own. Shan et al. (2012) 
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discovered that treating oxidized FKBP12.6-mutant mice models with S107 was able to reduce 
Ca2+ SR leak, however in FKBP12.6 knockout mice models, S107 imposed no effect on RyR2. 
They concluded that S107 cannot elicit a drug response without the presence of FKBP12.6. 
Lacampagne et al. (2017) revealed that the presence of S107 in WT mice did not affect RyR2 
or FKBP12.6 levels, suggesting that S107 does not increase FKBP12.6 levels but rather enables 
more of it to bind RyR2, therefore affecting Ca2+ activity. If these are continually consistent 
with other studies, this could suggest a potential therapeutic pathway of targeting AD-observed 
Ca2+ leak to prevent AD-like symptoms. 
 
On the contrary, findings of George et al. (2003) highlighted that S107 was able to reduce SR 
Ca2+ leak in CPVT mutant models, however their study also noted that CPVT SR Ca2+ leak 
happened independently of FKBP12.6, suggesting that FKBP12.6 may not necessarily be 
needed for S107 to have an effect on RyR2-mediated Ca2+ leak. Again, this could be because 
the study used cardiomyocytes that, as aforementioned, have a low expression of FKBP12.6 
and predominantly express FKBP12 (Jeyakumar et al., 2001). 
 
Results of Hunt et al. (2007) showed that in both HEK293 cells and cardiomyocytes, K201, a 
derivative of S107, was able to reduce Ca2+ leak out of RyR2 independent of FKBP12.6. 
However, in order to test whether FKBP12.6 was required for K201 to have an effect, they 
used FK506, which has been shown to cause FKBP12.6 dissociation from RyR2. Unfortunately, 
they did not examine the effects of FKBP12.6 with RyR2 without FK506 drug treatment. On 
the contrary, Xiao et al. (2007) suggested that FK506 has an effect on SOICR activity that is 
FKBP12.6-independent, perhaps suggesting that FK506 has a direct effect on RyR2. This could 




Overall, differences in models, transfection efficiency, and the use of FK506 and its role on 
RyR2 directly, could explain the differences seen between my findings and the findings of 
contrasting studies. In terms of AD, S107 would be an effective form of treatment for AD, 
provided there is an abundant amount of FKBP12.6 in the brain. 
 
4.2 Alterations in RyR2 arrangement 
In addition to function, this study also investigated the effect of both FKBP12.6 and S107 on 
RyR2 arrangement using dSTORM imaging (Section 3.1.2), using immunocytochemistry to 
label RyR2 and FKBP12.6 with fluorescent tags (Section 3.1.1). This was to determine if the 
mechanism by which the function of RyR2 changes is due to structural rearrangement of RyR2 
clusters. 
 
4.2.1 Confirmation of the expression of RyR2 and FKBP12.6 
All of the functional data above assumed that there was adequate expression of RyR2 and 
FKBP12.6. Caffeine-mediated Ca2+ release and SOICR can only occur through RyR2, meaning 
it must have been expressed in all cells analyzed. Similarly, the significant reduction in SOICR 
occurrence in cells transfected with FKBP12.6 suggests it must also have been present. 
However, to confirm the presence of RyR2 and FKBP12.6, immunolabelling was performed 
(Figures 4.7-4.9). 
 
Although there was visible co-localization of RyR2 and FKBP12.6 (Figure 4.8 & 4.9), the 
overall immunolabelling was not very successful, preventing detailed analysis. There was low 
signal to noise, driven by a weak signal and a lot of background staining, especially labelling 
for FKBP12.6 (Figure 8B). Why this is the case is unclear as the methodology was a 
standardized protocol. It could have been due to incomplete permeabilization with Triton X-
100, preventing access to the interior of the cell during the labelling steps. It could also be that 
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the primary antibodies failed to stay onto the coverslips during its overnight incubation period. 
For both steps, the surface tension of the solution keeps the solution on the coverslip. In my 
experiments, the solution had leaked off the coverslip, so it is uncertain how long the cells were 
exposed to the solution. Unfortunately, there was not enough time to repeat these experiments. 
However, the labelling, albeit poor, combined with the functional data gives confidence that 
all of the cells expressed RyR2 and were successfully transfected with FKBP12.6. 
 
4.2.2 RyR2 structural arrangement 
Although the labelling was not as good as hoped, it was deemed sufficient to try and attempt 
super-resolution imaging. dSTORM imaging produced usable images that allowed me to 
determine the number of channels within a cluster, the distance of each cluster across the area 
of a cell, and the packing (density) of RyR2 channels. The results showed that there was no 
significant difference in RyR2 count, spread, and density between RyR2-only cells and cells 
co-expressing FKBP12.6 with S107 (Figure 3.11). Whilst this was expected for RyR2 spread, 
this was not expected for RyR2 count and density. The initial hypothesis posed that there would 
be tighter and smaller clusters forming with FKBP12.6 an S107 treatment, implicating that 
RyR2 density would increase whilst RyR2 spread and RyR2 count would decrease. RyR2 
density would increase, as we would expect more RyR2 channels to be packed more tightly 
together. On the other hand, RyR2 count would decrease, as RyR2 channels would form 
smaller clusters and be more tightly packed within that area. Thus, as the mean cluster area was 
hypothesized to decrease, RyR2 count would also decrease. RyR2 spread was expected to 
remain the same, as FKBP12.6 does not change the number of RyR2 clusters activated. This 
suggests that FKBP12.6 does not affect the number of RyR2 clusters present to reduce leak, 
but rather stabilizes the RyR2 channels within the clusters to reduce Ca2+ leak . Although this 
was not expected to change, it indicates that FKBP12.6 alters the way within a cluster behaves. 
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However, there was a lot of variability between the individual cells and only a low number 
were able to be analyzed (n = 5 for cells with FKBP12.6 and S107, n = 6 for cells with RyR2-
only). Previous studies characterizing RyR2 clusters typically require 9-10 cells per condition 
(Shen et al., 2019; Munro et al., 2021). Thus, I believe these results are inconclusive, as the 
sample size is too small to have any sort of significance.  
 
Currently, there are a lack of studies using dSTORM in HEK293 cells, however dSTORM has 
been shown to be a good way of visualizing and obtaining measurements of 3D structures 
(Shen et al., 2019; Asghari et al., 2020). 3D dSTORM in healthy cardiomyocytes showed that 
there was approximately 15 RyR2 channels per cluster (Shen et al., 2019). Asghari et al. (2020) 
revealed similar findings, showing that there is a mean number of 18.5 RyR2 channels per 
cluster. Their study also studied the effect of FKBP12.6 on RyR2 arrangement, showing that 
with FKBP12.6, the mean number of RyR2 tetramers per cluster dropped to 11.5. Their 
measurements also showed that the mean cluster area decreased with FKBP12.6 present from 
27.3 (control) to 13.2 (FKBP12.6). This is what we expected to see from our results, and with 
S107, the mean cluster area would further reduce, as well as the number of RyR2 channels per 
cluster (Figure 4.1). Asghari et al. (2020) saw that their nearest neighbor distances between 
channels within a cluster was reduced, which was what I expected to see in my results, 
suggesting that tighter clusters are forming and therefore there is a reduction in Ca2+ leak. They 
also showed that the density of RyR2 increases with FKBP12.6 present in comparison to RyR2-
only cells. Many RyR2 studies have indicated that RyR2 arrangement and organization has an 
influence over Ca2+ spark frequency (Walker et al., 2015). However, my results show otherwise 
that there is no difference in channel packing, and density of RyR2 channels in clusters between 
RyR2 and RyR2 cells co-expressing FKBP12.6 and treated with S107 despite changes in the 
susceptibility to SOICR.  
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The imaging software, PYMEAcquire, picks up the number of events based on a threshold 
level set. Due to poor immunolabelling of RyR2, the poor signal-to-noise would cause the 
software to include some background, creating false events. This could explain the large spread 
of variability within the data. Others in the lab have performed dSTORM on HEK293 cells 
expressing RyR2 and show more defined clusters in a perinuclear region of the cell (Figure 
4.2). This is consistent with the ER location of RyR2. Compared to my data, there are a greater 
number of clusters of more uniformed size. This may indicate that my poor labelling led to 
some clusters being missed and the software “creating: clusters from noise within the nuclear 
region. Irrespective of the shortcomings, my data shows that there RyR2 clusters are the same 




Figure 4.1 dSTORM images taken of control vs. FKBP12.6-treated rat myocytes. Image adapted and taken 




Figure 4.2 dSTORM image of HEK293 RyR2 cells at 20 hours after induction. (A) Image from Tanner (2021). 
(B) My dSTORM image of RyR2-only cells. Scalebar for all images is 20µm. 
 
4.3 Limitations & future directions 
4.3.1 RyR2 cell induction 
As cells were induced between 14-22 hours prior to imaging, the large range in these induction 
times could affect RyR2 activity. Previous studies have demonstrated that at later times of 
induction, there is increasing RyR2 expression and therefore an increase in RyR2 activity (Xiao 
et al., 2007). To ensure that the time of induction of HEK293 cells does not affect RyR2 SOICR 
activity, RyR2 cells could be induced within a narrower time frame to eliminate the effects of 
the induction time on SOICR activity. To attempt to overcome this, the order of the different 
treatment groups were randomized to ensure that the mean time per group would be roughly 






4.3.2 HEK293 cell line & tissues 
While the HEK293 cell line was able to produce significant results and show that S107 has an 
effect on SOICR in cells co-expressing FKBP12.6, it would next be important to use other cell 
lines more applicable to AD. Some of this was part of my plans before the year was disrupted 
by COVID19. Initially, this could be cultured CA1 hippocampal neurons, but then should 
progress into brain slices from appropriate AD animal models, such as the APP-swe mouse 
model (Bussiere et al., 2017). Although functional data could not be recorded in human tissue, 
it would be interesting to extend the dSTORM imaging to AD patient samples which could be 
obtained from autopsies.  
 
4.3.3 Immunocytochemistry  
Poor immunolabelling prevented the confirmation of FKBP12.6 transfection. Therefore, it 
remains unknown what percentage of cells expressed FKBP1.6. For the functional assays, this 
means the effect of FKBP12.6 is likely under-estimated, as it is unlikely the efficiency was 
100%. Thus, some cells in the FKBP12.6 groups would not have FKBP12.6 expressed. 
However, previous studies in the lab have shown an efficiency of ~70%, suggesting the impact 
of non-expressing cells to be relatively low. Improving the immunolabelling technique would 
allow this to be confirmed in these experiments. Alternatively, FKBP12.6-stably expressing 
cells could be generated in the future to avoid this issue. 
 
Due to time constraints, dSTORM imaging was only performed on RyR2-only cells and cells 
co-expressing FKBP12.6 and treated with S107. These were chosen as the functional assay 
demonstrated that the combination of FKBP12.6 and S107 had the largest effect on the 
occurrence of SOICR, and was the only treatment group to exhibit a significant reduction in 
the magnitude of SOICR. Due to time constraints, I was unable to follow-up with other 
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treatment groups using these techniques. Combined with the few cells imaged this means that 
the results remain inconclusive.  
 
Besides using immunocytochemistry to confirm the presence of RyR2 and FKBP12.6, western 
blotting and co-immunoprecipitation could also be used to confirm the presence of the two 
proteins. Western blotting would be able to show any visual differences in the expression of 
the two proteins, looking at protein expression (Wehrens et al., 2003; Wang et al., 2020). A 
limitation of western blotting is that it shows the proteins are present, however it does not prove 
that there is any sort of interaction between the proteins.  Alternatively, co-
immunoprecipitation would confirm that the two proteins associate with one another, therefore 
elucidating if S107 is able to strengthen the association between FKBP12.6 and RyR2 (Mei et 
al., 2020). Although it is a very common and relatively simple technique, it does not show that 
two protein molecules definitely have a direct interaction. It is only able to indicate whether 
there is an interaction, but it is unable to specify whether or not this interaction is direct or 
indirect, as shown in studies such as Wang et al. (2020). Isothermal titration calorimetry could 
also be used to investigate if S107 has a direct effect on FKBP12.6, RyR2 or both, as isothermal 
titration calorimetry has been shown in the past to determine if there are direct interactions 
occurring between molecules (Hähle et al., 2019). Whilst this is a method that has not been 
used to determine the interaction between S107 and FKBP12.6, it is commonly used to look at 
drug interactions with other molecules. Although this is able to determine direct or indirect 
interactions between molecules, this is a time-consuming procedure that requires testing at 
increasing temperature increments (Baranauskiene et al., 2009). In the future, western blotting, 
co-immunoprecipitation and isothemal titration calorimetry can be performed to not only 
confirm the presence of these proteins, but also any interactions between RyR2, FKBP12.6, if 




4.3.4 dSTORM imaging 
dSTORM imaging was able to provide RyR2 count, spread, and density measurements. 
Unfortunately, as previously discussed, the sample size was too small. In addition, although 
immunocytochemistry was used to label RyR2 (488 nm) and FKBP12.6 (568 nm) structures, 
these were not viewed under the super-resolution microscope. This would’ve given an 
indication as to which cells co-expressed FKBP12.6 during dSTORM imaging. As a result, 
although I was able to confirm the presence of both proteins as well as their colocalization with 
one another, it cannot be certain that within the combination treatment, cells co-expressing 
FKBP12.6 were imaged using dSTORM. This could explain why there was no observable 
difference between RyR2-only cells and cells with FBP12.6 and S107, and could explain the 
variability within the data. Moreover, a general limitation of dSTORM also applies. Despite 
the huge increase in resolution compared to conventional microscopy, the number of channels 
within a cluster remains a theoretical value as it assumes an ordered orientation of individual 
proteins within a cluster (Yin & Lai, 2000; Shen et al., 2019). This is because dSTORM 
microscopy unfortunately lacks the resolution to view single proteins within a cluster. Other 
imaging techniques could be used to determine this, in the future. Options include techniques 
such as electron tomography and DNA-PAINT, both of which have been used to study RyR2 
previously (Jayasinghe et al., 2018; Hurley et al., 2021).  
 
Asghari et al. (2020) used electron tomography to observe the arrangement of RyR2 and its 
organization within clusters (Figure 3). They were able to determine if RyR2 clusters formed 
a “checkerboard” formation or more of a “side-to-side” arrangement, as tomograms allowed 
them to determine the orientation and distribution of RyR2 clusters within a cell.  Furthermore, 
DNA-PAINT has been shown to have better resolution than dSTORM imaging as it has more 
 56 
precision in the localization of RyR2, pinpointing individual positions of single RyR2 channels 




Figure 4.3 Electron tomographical images of a single rat myocyte outlined with RyR2 clusters identified. 
Images adapted and taken from (Asghari et al., 2020).  
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5 Conclusion 
To conclude, the findings presented in this thesis indicate that FKBP12.6 is able to reduce  Ca2+ 
leak (SOICR) occurrence and when combined with  S107, its magnitude. Additionally, the data 
show that without FKBP12.6, S107 does not have an effect on SOICR. This is consistent with 
previous studies in the heart and brain. However, the data is inconclusive as to whether RyR2 
arrangement is altered in cells due to the presence of FKBP12.6 and S107. This is due to: (1) 
poor immunolabelling and (2) a small sample size. If my findings are consistent with findings 
of other studies, S107 treatment by stabilizing the RyR2-FKBP12.6 complex could be a 
potential therapeutic treatment to alleviate AD-like symptoms. Before being able to come to 
this conclusion, further studies would need to be done. Further studies should use dSTORM 
imaging in combination with other imaging modalities, such as DNA-PAINT and tomography 
to examine changes in RyR2 arrangement and orientation under FKBP12.6 and S107 treatment. 
Moreover, both functional and structural assays should be repeated in cultured CA1 
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